Cytokines as mediators of chemotherapy-associated cognitive changes: Current evidence, limitations and directions for future research

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Cheung, Yin Ting ^a,b   Lim, Si Rong ^a   Ho, Han Kiat ^a   Chan, Alexandre ^a,b  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b DIVISION OF MEDICAL ONCOLOGY   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTILEUKEMIC AGENT; ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOKINE; DOXORUBICIN; FLUOROURACIL; INTERLEUKIN 1BETA; INTERLEUKIN 6; IRINOTECAN; LIPADAUNOCIN; METHOTREXATE; OXALIPLATIN; PREDNISONE; TAXANE DERIVATIVE; THALIDOMIDE; TOPOTECAN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; AGING; ANXIETY; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; COGNITIVE DEFECT; COLORECTAL CANCER; DEPRESSION; FATIGUE; GENETIC PREDISPOSITION; HEAD AND NECK CANCER; HEAVY-HEADEDNESS; HUMAN; LYMPHOMA; MEMORY DISORDER; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEX DIFFERENCE; SLEEP WAKING CYCLE; SYSTEMATIC REVIEW; THINKING IMPAIRMENT; UNSPECIFIED SIDE EFFECT; COGNITION; DRUG EFFECTS; METABOLISM; NEOPLASMS; PATHOPHYSIOLOGY;

ANTINEOPLASTIC AGENTS; COGNITION; CYTOKINES; HUMANS; NEOPLASMS;

EID: 84891921265     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0081234     Document Type: Article

References (105)

1. Jim HSL, Phillips KM, Chait S, Faul LA, Popa MA, et al. (2012) Meta-analysis of cognitive functioning in breast cancer survivors previously treated with standard-dose chemotherapy. J Clin Oncol 30:3578-3587.
2. Cheung YT, Maung Shwe HG, Tan YP, Fan GKT, Ng RCH, et al. (2012) Cognitive changes in multiethnic Asian breast cancer patients: A focus group study. Ann Oncol 23:2547-2552.
3. Vardy J (2009) Cognitive function in breast cancer survivors. Cancer Treat Res 151:387-419.
4. Cheung YT, Chui WK, Chan A (2011) Neuro-cognitive impairment in breast cancer patients: Pharmacological considerations. Crit Rev Oncol Hematol 83:99-111.
5. Munir F, Burrows J, Yarker J, Kalawsky K, Bains M (2010) Women's perceptions of chemotherapy-induced cognitive side affects on work ability: A focus group study. J Clin Nurs 19:1362-1370.
6. Boykoff N, Moieni M, Subramanian SK (2009) Confronting chemobrain: an in-depth look at survivors' reports of impact on work, social networks, and health care response. J Cancer Surviv 3:1-10.
7. Reid-Arndt SA, Hsieh C, Perry MC (2010) Neuropsychological functioning and quality of life during the first year after completing chemotherapy for breast cancer. Psychooncology 19:535-544.
8. Vardy J, Wefel JS, Ahles T, Tannock IF, Schagen SB (2008) Cancer and cancer-therapy related cognitive dysfunction: an international perspective from the Venice cognitive workshop. Ann Oncol 19:623-629. (Pubitemid 351461030)
9. Minisini A, Atalay G, Bottomley A, Puglisi F, Piccart M, et al. (2004) What is the effect of systemic anticancer treatment on cognitive function? Lancet Oncol 5:273-282. (Pubitemid 38541579)
10. Aluise CD, Sultana R, Tangpong J, Vore M, St Clair D, et al. (2010) Chemo brain (chemo fog) as a potential side effect of doxorubicin administration: role of cytokine-induced, oxidative/nitrosative stress in cognitive dysfunction. Adv Exp Med Biol 678:147-156.
11. Banks WA, Farr SA, Morley JE (2002) Entry of blood-borne cytokines into the central nervous system: effects on cognitive processes. Neuroimmunomodulation 10:319-327. (Pubitemid 36980741)
12. Cibelli M, Fidalgo AR, Terrando N, Ma D, Monaco C, et al. (2010) Role of interleukin-1beta in postoperative cognitive dysfunction. Ann Neurol 68:360-368.
13. Kronfol Z, Remick DG (2000) Cytokines and the brain: implications for clinical psychiatry. Am J Psychiatry 157:683-694. (Pubitemid 30249643)
14. Licinio J, Kling MA, Hauser P (1998) Cytokines and brain function: relevance to interferon-alpha-induced mood and cognitive changes. Semin Oncol 25:30-38. (Pubitemid 28093153)
15. Myers JS, Pierce J, Pazdernik T (2008) Neurotoxicology of chemotherapy in relation to cytokine release, the blood-brain barrier, and cognitive impairment. Oncol Nurs Forum 35:916-920.
16. Myers JS (2010) The possible role of cytokines in chemotherapy-induced cognitive deficits. Adv Exp Med Biol 678:119-123.
17. Raffa RB (2011) A proposed mechanism for chemotherapy-related cognitive impairment ('chemo-fog'). J Clin Pharm Ther 36:257-259.
18. Dunlop RJ, Campbell CW (2000) Cytokines and advanced cancer. J Pain Symptom Manage 20:214-232.
19. Kenis G, Maes M (2002) Effects of antidepressants on the production of cytokines. Int J Neuropsychopharmacol 5:401-412. (Pubitemid 35470359)
20. Lee BN, Dantzer R, Langley KE, Bennett GJ, Dougherty PM, et al. (2004) A cytokine-based neuroimmunologic mechanism of cancer-related symptoms. Neuroimmunomodulation 11:279-292. (Pubitemid 39194326)
21. Madeleine MM, Johnson LG, Malkki M, Resler AJ, Petersdorf EW, et al. (2011) Genetic variation in proinflammatory cytokines IL6, IL6R, TNF-region, and TNFRSF1A and risk of breast cancer. Breast Cancer Res Treat 129:887-899.
22. Meyers CA, Albitar M, Estey E (2005) Cognitive impairment, fatigue, and cytokine levels in patients with acute myelogenous leukemia or myelodysplastic syndrome. Cancer 104:788-793. (Pubitemid 41113679)
23. Miller AH, Ancoli-Israel S, Bower JE, Capuron L, Irwin MR (2008) Neuroendocrine-immune mechanisms of behavioral comorbidities in patients with cancer. J Clin Oncol 26:971-982. (Pubitemid 351409339)
24. Pfeilschifter J, Koditz R, Pfohl M, Schatz H (2002) Changes in proinflammatory cytokine activity after menopause. Endocr Rev 23:90-119. (Pubitemid 34185307)
25. Pusztai L, Mendoza TR, Reuben JM, Martinez MM, Willey JS, et al. (2004) Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy. Cytokine 25:94-102. (Pubitemid 38096266)
26. Reyes-Gibby CC, Spitz M, Wu X, Merriman K, Etzel C, et al. (2007) Cytokine genes and pain severity in lung cancer: exploring the influence of TNF-alpha-308 G/A IL6-174G/C and IL8-251T/A. Cancer Epidemiol Biomarkers Prev 16:2745-2751. (Pubitemid 351196331)
27. Rich T, Innominato PF, Boerner J, Mormont MC, Iacobelli S, et al. (2005) Elevated serum cytokines correlated with altered behavior, serum cortisol rhythm, and dampened 24-hour rest-activity patterns in patients with metastatic colorectal cancer. Clin Cancer Res 11:1757-1764. (Pubitemid 40471837)
28. Seigers R, Fardell JE (2011) Neurobiological basis of chemotherapy-induced cognitive impairment: a review of rodent research. Neurosci Biobehav Rev 35:729-741.
29. Seruga B, Zhang H, Bernstein LJ, Tannock IF (2008) Cytokines and their relationship to the symptoms and outcome of cancer. Nat Rev Cancer 8:887-899.
30. Wilson CJ, Finch CE, Cohen HJ (2002) Cytokines and cognition-the case for a head-to-toe inflammatory paradigm. J Am Geriatr Soc 50:2041-2056. (Pubitemid 35462453)
31. Deeken JF, Loscher W (2007) The blood-brain barrier and cancer: transporters, treatment, and Trojan horses. Clin Cancer Res 13:1663-1674. (Pubitemid 46952931)
32. Konsman JP, Vigues S, Mackerlova L, Bristow A, Blomqvist A (2004) Rat brain vascular distribution of interleukin-1 type-1 receptor immunoreactivity: relationship to patterns of inducible cyclooxygenase expression by peripheral inflammatory stimuli. J Comp Neurol 472:113-129. (Pubitemid 38393311)
33. Anthony DC, Bolton SJ, Fearn S, Perry VH (1997) Age-related effects of interleukin-1 beta on polymorphonuclear neutrophil-dependent increases in blood-brain barrier permeability in rats. Brain 120(Pt 3):435-444. (Pubitemid 27153636)
34. Joshi G, Aluise CD, Cole MP, Sultana R, Pierce WM, et al. (2010) Alterations in brain antioxidant enzymes and redox proteomic identification of oxidized brain proteins induced by the anti-cancer drug adriamycin: implications for oxidative stress-mediated chemobrain. Neuroscience 166:796-807.
35. Joshi G, Hardas S, Sultana R, St Clair DK, Vore M, et al. (2007) Glutathione elevation by gamma-glutamyl cysteine ethyl ester as a potential therapeutic strategy for preventing oxidative stress in brain mediated by in vivo administration of adriamycin: Implication for chemobrain. J Neurosci Res 85:497-503.
36. Joshi G, Sultana R, Tangpong J, Cole MP, St Clair DK, et al. (2005) Free radical mediated oxidative stress and toxic side effects in brain induced by the anti cancer drug adriamycin: insight into chemobrain. Free Radic Res 39:1147-1154. (Pubitemid 41601416)
37. Tangpong J, Cole MP, Sultana R, Joshi G, Estus S, et al. (2006) Adriamycininduced, TNF-alpha-mediated central nervous system toxicity. Neurobiol Dis 23:127-139. (Pubitemid 44192385)
38. Lynch MA (2010) Age-related neuroinflammatory changes negatively impact on neuronal function. Front Aging Neurosci 1:6.
39. Aluise CD, Miriyala S, Noel T, Sultana R, Jungsuwadee P, et al. (2011) 2-Mercaptoethane sulfonate prevents doxorubicin-induced plasma protein oxidation and TNF-alpha release: implications for the reactive oxygen species-mediated mechanisms of chemobrain. Free Radic Biol Med 50:1630-1638.
40. Tangpong J, Cole MP, Sultana R, Estus S, Vore M, et al. (2007) Adriamycinmediated nitration of manganese superoxide dismutase in the central nervous system: insight into the mechanism of chemobrain. J Neurochem 100:191-201. (Pubitemid 46090774)
41. Kesler S, Janelsins M, Koovakkattu D, Palesh O, Mustian K, et al. (2013) Reduced hippocampal volume and verbal memory performance associated with interleukin-6 and tumor necrosis factor-alpha levels in chemotherapytreated breast cancer survivors. Brain Behav Immun 30 Suppl: S109-16.
42. Das S, Basu A (2008) Inflammation: a new candidate in modulating adult neurogenesis. J Neurosci Res 86:1199-1208. (Pubitemid 351571895)
43. Marsland AL, Gianaros PJ, Abramowitch SM, Manuck SB, Hariri AR (2008) Interleukin-6 covaries inversely with hippocampal grey matter volume in middle-aged adults. Biol Psychiatry 64:484-490.
44. McAfoose J, Baune BT (2009) Evidence for a cytokine model of cognitive function. Neurosci Biobehav Rev 33:355-366.
45. Vardy J, Dhillon H, Xu W, Rourke S, Dodd A, et al. (2012) Cognitive function in colorectal cancer patients: a longitudinal prospective study. Interational Cognition and Cancer Task Force [Abstract].
46. Vardy JL, Dhillon H, Xu W, Dodd A, Park A, et al. (2009) Cognitive function and fatigue in colorectal cancer (CRC) patients: Baseline assessments prior to chemotherapy. J Clin Oncol 27:15S (suppl; abstr 9557) [Abstract].
47. Vardy J, Rourke S, Galica J, Pond G, Park A, et al. (2006) Cytokine levels in patients (pts) with localized colorectal cancer (CRC) after surgery and their relationship to fatigue and cognitive function. Clin Oncol 24:18S (suppl; abstr 3623) [Abstract].
48. Vardy J, Rourke S, Pond GR, Galica J, Park A, et al. (2007) Cognitive function and fatigue in cancer patients after chemotherapy: A longitudinal cohort study in patients with colorectal cancer (CRC). J Clin Oncol 25:18S (suppl; abstr 9099) [Abstract].
49. Booth CM, Vardy J, Crawley A, Rourke S, Pond G, et al. (2006) Cognitive impairment associated with chemotherapy for breast cancer: An exploratory case-control study. J Clin Oncol 24:18S (suppl; abstr 8501) [Abstract].
50. Knobel H, Loge JH, Nordoy T, Kolstad AL, Espevik T, et al. (2000) High level of fatigue in lymphoma patients treated with high dose therapy. J Pain Symptom Manage 19:446-456. (Pubitemid 30447370)
51. Gan HK, Bernstein LJ, Brown J, Ringash J, Vakilha M, et al. (2011) Cognitive functioning after radiotherapy or chemoradio therapy for head-and-neck cancer. IntJ Radiat Oncol Biol Phys 81:126-134.
52. Ganz PA, Castellon SA, Silverman DHS, Kwan L, Bower JE, et al. (2011) Does circulating tumor necrosis factor (TNF) play a role in post-chemotherapy cerebral dysfunction in breast cancer survivors (BCS) ?. J Clin Oncol 29:18S (suppl; abstr 9008) [Abstract].
53. Ganz PA, Bower JE, Kwan L, Castellon SA, Silverman DHS, et al. (2013) Does tumor necrosis factor-alpha (TNF-a) play a role in post-chemotherapy cerebral dysfunction? Brain Behav Immun 30 Suppl: S99-108.
54. Ganz PA, Kwan L, Castellon SA, Bower JE, Silverman DHS, et al. (2012) Cognitive complaints in breast cancer patients: Associations with therapy and cytokine markers. International Cognition and Cancer Task Force [Abstract].
55. Janelsins MC, Mustian KM, Palesh OG, Mohile SG, Peppone LJ, et al. (2011) Differential expression of cytokines in breast cancer patients receiving different chemotherapies: implications for cognitive impairment research. Support Care Cancer 20:831-839.
56. Reitan RM (1958) Validity of the Trail Making Test as an Indicator of Organic Brain Damage. Percept Mot Skills 8:271-286.
57. Shapiro AM, Benedict RH, Schretlen D, Brandt J (1999) Construct and Concurrent Validity of the Hopkins Verbal Learning Test-revised. Clin Neuropsychol 13:348-358. (Pubitemid 30040145)
58. Fray PJ, Robbins TW (1996) CANTAB Battery: Proposed Utility in Neurotoxicology. Neurotoxicol Teratol 18:499-504. (Pubitemid 26288719)
59. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, et al. (1993) The European Organisation for Research and Treatment of Cancer QLQ-C30: A Quality-of-life Instrument for Use in International Clinical Trials in Oncology. J Natl Cancer Inst: 365-376. (Pubitemid 23073154)
60. Wagner LI, Sweet J, Butt Z, Lai J-S, Cella D (2009) Measuring Patient Self-Reported Cognitive Function: Development of the Funcdonal Assessment of Cancer Therapy-Cognitive Function Instrument. J Support Oncol 7:W32-W39.
61. Sioka C, Kyritsis AP (2009) Central and peripheral nervous system toxicity of common chemotherapeutic agents. Cancer Chemother Pharmacol 63:761-767.
62. Seigers R, Timmermans J, van der Horn HJ, de Vries EF, Dierckx RA, et al. (2010) Methotrexate reduces hippocampal blood vessel density and activates microglia in rats but does not elevate central cytokine release. Behav Brain Res 207:265-272.
63. Foley JJ, Raffa RB, Walker EA (2008) Effects of chemotherapeutic agents 5-fluorouracil and methotrexate alone and combined in a mouse model of learning and memory. Psychopharmacology (Berl) 199:527-538.
64. Correa DD, Ahles TA (2008) Neurocognitive changes in cancer survivors. CancerJ 14:396-400.
65. Schagen SB, Muller MJ, Boogerd W, Rosenbrand RM, van Rhijn D, et al. (2002) Late effects of adjuvant chemotherapy on cognitive function: a follow-up study in breast cancer patients. Ann Oncol 13:1387-1397.
66. O'Shaughnessy JA (2003) Chemotherapy-induced cognitive dysfunction: a clearer picture. Clin Breast Cancer 4 Suppl 2:S89-94. (Pubitemid 38028835)
67. Argyriou AA, Assimakopoulos K, Iconomou G, Giannakopoulou F, Kalofonos HP (2011) Either Called "Chemobrain" or "Chemofog", the Long-Term Chemotherapy-Induced Cognitive Decline in Cancer Survivors Is Real. J Pain Symptom Manage 41:126-139.
68. Purdue MP, Lan Q, Bagni R, Hocking WG, Baris D, et al. (2011) Prediagnostic serum levels of cytokines and other immune markers and risk of non-hodgkin lymphoma. Cancer Res 71:4898-4907.
69. Rothman N, Skibola CF, Wang SS, Morgan G, Lan Q, et al. (2006) Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: A report from the InterLymph Consortium. Lancet Oncol 7:27-38. (Pubitemid 43025390)
70. Unfer TC, Conterato GM, da Silva JC, Duarte MM, Emanuelli T (2006) Influence of hormone replacement therapy on blood antioxidant enzymes in menopausal women. Clin Chim Acta 369:73-77. (Pubitemid 43783393)
71. Lee DC, Im JA, Kim JH, Lee HR, Shim JY (2005) Effect of long-term hormone therapy on telomere length in postmenopausal women. Yonsei Med J 46:471-479.
72. Ganz PA, Greendale GA, Petersen L, Kahn B, Bower JE (2003) Breast cancer in younger women: reproductive and late health effects of treatment. J Clin Oncol 21:4184-4193. (Pubitemid 46606187)
73. Knobf MT (1986) Physical and psychologic distress associated with adjuvant chemotherapy in women with breast cancer. J Clin Oncol 4:678-684. (Pubitemid 16114714)
74. Malkin CJ, Pugh PJ, Jones RD, Kapoor D, Channer KS, et al. (2004) The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men. J Clin Endocrinol Metab 89:3313-3318. (Pubitemid 38951897)
75. Beauchet O (2006) Testosterone and cognitive function: Current clinical evidence of a relationship. Eur J Endocrinol 155:773-781. (Pubitemid 46040613)
76. Amore M, Innamorati M, Costi S, Sher L, Girardi P, et al. (2012) Partial androgen deficiency, depression, and testosterone supplementation in aging men. Int J Endocrinol 2012.
77. Ahles TA, Root JC, Ryan EL (2012) Cancer- and cancer treatment-associated cognitive change: An update on the state of the science. J Clin Oncol 30:3675-3686.
78. Peterson PK, Chao CC, Carson P, Hu S, Nichol K, et al. (1994) Levels of tumor necrosis factor alpha, interleukin 6, interleukin 10, and transforming growth factor beta are normal in the serum of the healthy elderly. Clin Infect Dis 19:1158-1159. (Pubitemid 24380038)
79. Wei J, Xu H, Davies JL, Hemmings GP (1992) Increase of plasma IL-6 concentration with age in healthy subjects. Life Sci 51:1953-1956.
80. Hager K, Machein U, Krieger S, Platt D, Seefried G, et al. (1994) Interleukin-6 and selected plasma proteins in healthy persons of different ages. Neurobiol Aging 15:771-772. (Pubitemid 24360175)
81. Ahles TA, Saykin AJ, McDonald BC, Y L, Furstenberg CT, et al. (2010) Longitudinal assessment of cognitive changes associated with adjuvant treatment for breast cancer: impact of age and cognitive reserve. J Clin Oncol 28:4434-4440.
82. Ahles TA, Saykin AJ (2007) Candidate mechanisms for chemotherapy-induced cognitive changes. Nat Rev Cancer 7:192-201.
83. Vandenbroeck K, Goris A (2003) Cytokine gene polymorphisms in multifactorial diseases: gateways to novel targets for immunotherapy? Trends Pharmacol Sci 24:284-289. (Pubitemid 36725003)
84. Corsi-Cabrera M, Arce C, Del Rio-Portilla IY, Perez-Garci E, Guevara MA (1999) Amplitude reduction in visual event-related potentials as a function of sleep deprivation. Sleep 22:181-189. (Pubitemid 29143216)
85. McCarthy ME, Waters WF (1997) Decreased attentional responsivity during sleep deprivation: orienting response latency, amplitude, and habituation. Sleep 20:115-123. (Pubitemid 27194749)
86. Pilcher JJ, Walters AS (1997) How sleep deprivation affects psychological variables related to college students' cognitive performance. J Am Coll Health 46:121-126. (Pubitemid 27509736)
87. Schubert C, Hong S, Natarajan L, Mills PJ, Dimsdale JE (2007) The association between fatigue and inflammatory marker levels in cancer patients: a quantitative review. Brain Behav Immun 21:413-427. (Pubitemid 46528677)
88. Antoni MH, Lechner S, Diaz A, Vargas S, Holley H, et al. (2009) Cognitive behavioral stress management effects on psychosocial and physiological adaptation in women undergoing treatment for breast cancer. Brain Behav Immun 23:580-591.
89. Raison CL, Demetrashvili M, Capuron L, Miller AH (2005) Neuropsychiatric adverse effects of interferon-alpha: recognition and management. CNS Drugs 19:105-123. (Pubitemid 40321763)
90. Pullens MJJ, De Vries J, Roukema JA (2010) Subjective cognitive dysfunction in breast cancer patients: A systematic review. Psycho oncology 19:1127-1138.
91. Wefel JS, Vardy J, Ahles T, Schagen SB (2011) International Cognition and Cancer Task Force recommendations to harmonise studies of cognitive function in patients with cancer. Lancet Oncol 12:703-708.
92. De Almodovar CR, Lambrechts D, Mazzone M, Carmeliet P (2009) Role and therapeutic potential of VEGF in the nervous system. Physiol Rev 89:607-648.
93. Leng SX, McElhaney JE, Walston JD, Xie D, Fedarko NS, et al. (2008) ELISA and multiplex technologies for cytokine measurement in inflammation and aging research. J Gerontol A Biol Sci Med Sci 63:879-884.
94. Sachdeva N, Asthana D (2007) Cytokine quantitation: Technologies and applications. Front Biosci 12:4682-4695.
95. DuPont NC, Wang K, Wadhwa PD, Culhane JF, Nelson EL (2005) Validation and comparison of luminex multiplex cytokine analysis kits with ELISA: Determinations of a panel of nine cytokines in clinical sample culture supernatants. J Reprod Immunol 66:175-191. (Pubitemid 41073746)
96. Dupont NC, Wang K, Wadhwa PD, Culhane JF, Nelson EL (2005) Validation and comparison of luminex multiplex cytokine analysis kits with ELISA: determinations of a panel of nine cytokines in clinical sample culture supernatants. J Reprod Immunol 66:175-191. (Pubitemid 41073746)
97. Khan SS, Smith MS, Reda D, Suffredini AF, McCoy JP, Jr. (2004) Multiplex bead array assays for detection of soluble cytokines: comparisons of sensitivity and quantitative values among kits from multiple manufacturers. Cytometry B Clin Cytom 61:35-39. (Pubitemid 39223368)
98. Lash GE, Scaife PJ, Innes BA, Otun HA, Robson SC, et al. (2006) Comparison of three multiplex cytokine analysis systems: Luminex, SearchLight and FAST Quant. J Immunol Methods 309:205-208. (Pubitemid 43190817)
99. Jolliffe IT (2002) Principal Component Analysis, Second Edition. Library of Congress Cataloging-in-Publication Data: 487.
100. Yennurajalingam S, Reuben JM, Palmer JL, Cohen EN, Tin S, et al. (2011) Cancer-related-fatigue (CRF) is associated with IL-6, IL-6R and IL-17, while IL-8 and IL-6 are associated with no improvement of CRF after treatment. Support Care Cancer 19:S233.
101. Long JM, Lee GD, Kelley-Bell B, Spangler EL, Perez EJ, et al. (2011) Preserved learning and memory following 5-fluorouracil and cyclophosphamide treatment in rats. Pharmacol Biochem Behav 100:205-211.
102. Winocur G, Henkelman M, Wojtowicz JM, Zhang H, Binns MA, et al. (2012) The effects of chemotherapy on cognitive function in a mouse model: A prospective study. Clin Cancer Res 18:3112-3121.
103. Christie LA, Acharya MM, Parihar VK, Nguyen A, Martirosian V, et al. (2012) Impaired cognitive function and hippocampal neurogenesis following cancer chemotherapy. Clin Cancer Res 18:1954-1965.
104. Walker EA, Foley JJ, Clark-Vetri R, Raffa RB (2011) Effects of repeated administration of chemotherapeutic agents tamoxifen, methotrexate, and 5-fluorouracil on the acquisition and retention of a learned response in mice. Psychopharmacology 217:539-548.
105. Hurria A, Somlo G, Ahles T (2007) Renaming "chemobrain". Cancer Invest 25:373-377.